ADM Tronics Achieves Development Milestone for Alvio Respiratory Therapy Platform

October 15, 2018

NORTHVALE, NJ / ACCESSWIRE / October 15, 2018 / ADM Tronics Unlimited, Inc. (OTCQB: ADMT) has achieved a milestone in the development of the Alvio Respiratory Therapy platform "Alvio™"). ADMT has completed development and engineering to

NORTHVALE, NJ / ACCESSWIRE / October 15, 2018 / ADM Tronics Unlimited, Inc. (OTCQB: ADMT) has achieved a milestone in the development of the Alvio Respiratory Therapy platform “Alvio™”). ADMT has completed development and engineering to bring Alvio to production-ready status. All components are now in place for the initial 100-unit production run, being assembled now. This initial run of Alvio devices will be deployed for patient and clinic testing. As announced last November, ADM entered into an agreement with QoL Devices, Inc., a private company (“QoL”) for development, regulatory activities and manufacturing of Alvio. The Alvio platform is targeted for use in non-regulated respiratory training applications as well as for medical respiratory indications.

“We are so pleased we are ready for production of our first Alvio units,” stated Bez Arkush, founder and President of QoL. “This is a significant milestone for our respiratory technology that has the potential to help millions of people. We are excited to have made this progress with ADMT.”

The initial Alvio production units are slated for user and clinic testing including testing at the Mayo Clinic under the direction of Dr. Bruce Johnson. Dr. Johnson has dedicated his research to improving treatment of patients with pulmonary conditions. Research prototypes of the Alvio platform were previously successfully evaluated in Dr. Johnson’s lab.

ADMT has developed and engineered all the supply chain components required to manufacture Alvio devices in ADMT’s FDA-registered medical device manufacturing facility. QoL and ADMT plan to first introduce a non-regulated version of Alvio for sale to consumers for breathing training, while preparing submission to FDA for clearance of Alvio for medical applications in the US and for CE marking for Europe.

A study was conducted at Children’s Hospital at Montefiore Medical Center in New York titled “Engagement and interest of children and their parents in a gaming device to assess lung function.” In the study, asthmatic children utilized the gaming functionality of the Alvio platform to facilitate lung function assessment of asthma monitoring to improve health outcomes. The results showed a highly significant result with 92% of children wanting to use the gaming function of the device and 95% of parents interested in using the games to better understand their child’s lung function. The study concluded, “This study supports the accessibility and interest in using a gaming device to assess lung function. Making lung function testing accessible and fun could increase use of testing to improve asthma management.”

Over 80 million people in the US and over 1 billion people worldwide suffer with respiratory challenges such as Asthma, COPD (chronic obstructive pulmonary disease) and CHF (congestive heart failure). These patients require special breathing monitoring, training, and therapeutic devices in the hospital and at home. Alvio’s cloud-connected devices can serve as an enabler to lower costs and improve patient outcomes across the continuum of care in the hospital and at home.

“We believe our devices are positioned to disrupt the $5+ billion US and the $6+ billion international respiratory therapy markets. Alvio is the world’s only fully integrated respiratory therapy platform, mobile connected, respiratory sensor and trainer that can redefine respiratory therapy and training markets,” continued Mr. Arkush.

Andre’ DiMino, ADMT President stated “We are excited to have reached this milestone in the development of Alvio which has the potential to help so many with debilitating respiratory problems. It is especially gratifying to me to be bringing forward a technology that can help children with asthma.” ADMT is an equity holder in QoL.

Alvio can provide an end-to-end solution for lung function testing, respiratory training, and data tracking, utilizing an interactive connection among patients, caregivers, health care providers, and payers. Alvio employs games and activities to incentivize patients to complete respiratory therapy, overcoming non-compliance issues that plague conventional respiratory devices. The Alvio platform can solve a major challenge in the healthcare market by offering the next generation of a combination of data and device connectivity - it’s Respiratory Therapy 2.0™.

About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Medical Device Design, Engineering, Regulatory and Manufacturing Services; Proprietary Electronic Medical Devices; and Eco-Friendly, Water-Based Formulations. The Company’s headquarters, laboratories, FDA-Registered medical device and manufacturing operations are inNorthvale, NJ. ADMT’s multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, such as 3-D prototyping, precision instrumentation and specialized software and peripherals, for research, development and commercialization of diversified technologies. Additional information is available at the Company’s website admtronics.com.

Except for historical information contained herein, the matters set forth in this news release are “forward looking” statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT’s SEC filings,news releases and other communications. The Company assumes no obligation to update information contained in this news release.

Contact: Andre’ DiMino201-767-6040,

SOURCE: ADM Tronics Unlimited, Inc.

Update hourly